Alzheimer's and age-matched control brains in combination with genetic models of somatostatin receptor deficiency to establish causality between defunct somatostatin signalling and noradrenergic neurodegeneration. In Alzheimer's disease, we found significantly reduced somatostatin protein expression in the temporal cortex, with aberrant clustering and bulging of tyrosine hydroxylase-immunoreactive afferents. As such, somatostatin receptor 2 (SSTR2) mRNA was highly expressed in the human LC, with its levels significantly decreasing from Braak stages III/IV and onwards, i.e., a process preceding advanced Alzheimer's pathology. The loss of SSTR2 transcripts in the LC neurons appeared selective, since tyrosine hydroxylase, dopamine β-hydroxylase, galanin or galanin receptor 3 mRNAs remained unchanged. We Abstract Alzheimer's disease and other age-related neurodegenerative disorders are associated with deterioration of the noradrenergic locus coeruleus (LC), a probable trigger for mood and memory dysfunction. LC noradrenergic neurons exhibit particularly high levels of somatostatin binding sites. This is noteworthy since cortical and hypothalamic somatostatin content is reduced in neurodegenerative pathologies. Yet a possible role of a somatostatin signal deficit in the maintenance of noradrenergic projections remains unknown. Here, we deployed tissue microarrays, immunohistochemistry, quantitative morphometry and mRNA profiling in a cohort of Electronic supplementary material The online version of this article
Introduction
Locus coeruleus (LC) is a key node in the mammalian brain sending projections to virtually all parts of the central nervous system [8, 40, 47, 72] . Its principal transmitter is noradrenaline (NA) [26] . The NA circuitry is involved in multiple physiological processes, including arousal, wakefulness, memory and motor functions as well as stress and mood regulation [9, 11, 17, 18, 39, 73, 97] . Several clinical studies indicate degenerative changes of the central noradrenergic system in Alzheimer's disease [12, 22, 44, 65, 103] as well as in Parkinson's disease and in Down's syndrome [44] . Impairment of this monoamine system is also involved in major depressive disorder [18, 93] . In fact, in Alzheimer's disease neuronal loss is more pronounced in LC than in the nucleus basalis of Meynert [119] . Recently, pre-tangle formation was found in the LC of young individuals, supporting the hypothesis that LC/subcoeruleus represents an early starting point for Alzheimer's disease pathology, even preceding the occurrence of cortical lesions [10, 13, 15] . Nevertheless, the cause(s) and underlying mechanism(s) of the early LC degeneration in Alzheimer's disease remain unclear.
In addition to direct functional deficits, NA lesions may induce amyloid formation via microglial inflammatory processes [52] and via loss of BDNF production or brain microvascular impairments [48, 85] . The currently used mouse models of Alzheimer's disease (transgenic mice expressing mutant forms of amyloid precursor protein (APP), presenilins and tau, singly or in combination), however, exhibit at most mild LC degeneration or no degeneration at all [45, 115] . In contrast, a selective chemical lesion of LC in APP-mutant mice induced by DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride) exacerbates the Aβ plaque load as well as cholinergic and spatial memory deficits [49, 115] . Also, when Ear2 −/− mice with an early noradrenergic deficit (Ear2 is an orphan nuclear receptor necessary for the development of LC neurons in mice) were crossed with APP/PS1 mice, they exhibited a significantly more severe impairment of spatial memory and hippocampal long-term potentiation than mice with either APP/PS1 mutation or loss of Ear2 alone [60] . Thus, these transgenic animal models are useful tools to study the consequences of noradrenergic impairment in experimental models of Alzheimer's disease but lack the inherent capacity to reveal candidate mechanism(s) underlying LC vulnerability.
Another, early established neurochemical hallmark of Alzheimer's disease is a substantial deficit of somatostatin (SST) in cortical areas and in the hypothalamus [20, 27, 58, 76, 89] . SST is a regulatory peptide originally discovered as the hypothalamic factor inhibiting growth hormone release [16, 107] and subsequently found to have wide distribution and multiple functions in the brain [34, 112] . SST acts via six subtypes of G-protein-coupled receptors, of which SSTR2(a) is one of the most abundant in the brain [54, 101, 112] . In Alzheimer's disease, SST was the most consistently reduced among all neuropeptides so far examined [20] . Likewise, SSTR2 mRNA expression was significantly decreased in the frontal and temporal cortices [42, 59] . Amyloid plaques show immunoreactivity for SST [74] . Also, polymorphisms of the SST gene are risks factors for Alzheimer's disease [111, 117] , albeit not confirmed in genome-wide association studies (GWAS). SST regulates the metabolism of Aβ through increasing neprilysin activity [90] . SST deficits were also detected in major depressive and bipolar disorders [64] . Moreover, SSTR2/SSTR3 modulation of monoamine systems may induce antidepressant effects in rats [32, 33] . Results on SST impairments in Alzheimer's disease mouse models are not consistent [53, 91] . However, one study on APPxPS1 mice reported an early decrease of SST expression and selective loss of SST-expressing interneurons in the hippocampus [84] , which was also described in human postmortem samples [27, 58] . These observations could provide explanations for the intimate correlation of the decrease in SST levels and cognitive deficit in Alzheimer's disease [36] .
Interestingly, the density of SST binding sites is very high in the LC both in the rodent [35, 41] and human brain [21] , and SST has strong inhibitory effect on LC neurons in vitro [23, 55, 68, 79] and in vivo [104] . However, less attention has been paid to a potential contribution of the well-established SST impairment to the well-defined noradrenergic deficit in neurodegenerative disorders.
To fill this gap, we first examined the expression of SSTR2 in LC samples from Alzheimer's disease cases and age-matched control subjects and found a decrease already in individuals with intermediate Alzheimer's disease neuropathological changes, Braak III-IV stage. Then we studied the potential role of SST receptors in the maintenance of the noradrenergic system in transgenic animal strains. Thus, the morphology and neurochemistry of neurocircuitiry were examined in Sstr1, Sstr2 and Sstr4 knockout animals with special attention to the monoaminergic systems. We show that the deletion of Sstr2, but not the other two SST receptors, results in a selective, global and progressive noradrenergic axonal degeneration.
Materials and experimental procedures
Detailed descriptions of human brains, Sstr knockout/ LacZ-knockin mice strains and methods are provided in the Supplementary Information (SI).
Immunohistochemistry on perfused human brains
Human brains (N = 2; Suppl. Brains were removed 4 h after death. Both internal carotid and vertebral arteries were cannulated, the brains were perfused as described [105] . Double-immunostaining procedure, confocal analysis and micrograph production were performed as described for animal tissue.
Quantitative PCR on human LC micro-punch samples Pieces of frozen human brainstems were obtained from the Human Tissue Bank, Semmelweis University, Hungary (HBTB, ethical permission numbers: 6008/8/2002/ETT and 32/1992/TUKEB). HBTB is a member of the BrainNet II Europe consortium. Procedures were in agreement with the Declaration of Helsinki. Neuropathological and histochemical examination of all brains, including classification of amyloid-β plaque burden, tau pathology and synuclein pathology was performed as described in the SI. Brains with Alzheimer's disease Braak stage V-VI (N = 7), with intermediate Alzheimer's disease neuropathologic changes (Braak stage III-IV) (N = 5) and age-matched controls with no neurodegenerative alterations and with no signs of clinical neuropsychiatric disease (N = 9) were selected (Suppl. Table 2) .
During the micro-punch procedure, 1.0-to 1.5-mm-thick coronal sections were cut at the level of LC, and 4-6 tissue pellets were collected bilaterally with the application of 0.7-mm inside diameter microdissection needles (two from each coronal section) and kept frozen at minus 70 °C pending analysis.
Total RNA from punched LC samples was extracted using the RNeasy Mini kit (Qiagen, Sollentuna, Sweden). TaqMan assay for tyrosine hydroxylase (TH) (Hs00165941_m1) was purchased from Applied Biosystems (Carlsbad, CA) and the amplification reaction was carried out using TaqMan assay master mix (Applied Biosystems). All other primers were purchased from SigmaAldrich (Suppl. Table 3 ). Gene expression was measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) on an Applied Biosystems 7000 Real-Time PCR system. Relative fold changes were calculated using the comparative CT method (2
−ΔΔCT
).
Tissue microarray (TMA) on human samples Formalin-fixed brains were obtained from the Dutch Brain Bank (NBB, ethical permission no. EPN 2013/474-31/2). Procedures were in agreement with the Declaration of Helsinki. Detailed neuropathological examination of all brains was performed as described in the SI.
A TMA block containing temporal cortex samples from Alzheimer's disease subjects (N = 7, Braak stage VI) and 9 age-matched controls (Suppl. Table 4) was constructed [56] . TMA slides were triple stained sequentially on a BOND-RX autostainer (Leica Microsystems, Wetzlar, Germany) for TH or SST, amyloid-β and tau-PHF using tyramide signal amplification (TSA) method [1] . Slides were scanned on the VSlide scanning system (Metasystems, Alltlussheim, Germany) using 20× objectives and appropriate filter sets. Immunostaining for SST, amyloid-β and tau-PHF was quantified by densitometry with the Image J 1.37v software (1.37v, NIH, MD).
Transgenic animals
Experiments were performed on (i) 2-week and 1-, 2-, 4-and 8-month-old male homozygote Sstr2 knockout/ LacZ knockin mice (Sstr2 ) [51] , (iv) three 15-month-old male homozygous TgAPParc transgenic mice [87, 88] , and on their wild-type littermates (WTs). Experimental procedures were approved by the local ethical committee (Stockholms norra djurförsöksetiska nämnd, N171-172/11), and conformed to the European Communities Council Directive #86/609/EEC and the "Principles of laboratory animal care" (NIH publication No. 86-23, revised 1985) . Particular care was taken to minimize the number of animals and their suffering throughout the experiments.
Fluorescence immunohistochemistry and microscopy/ confocal analysis of mice Mice were transcardially perfused with Zamboni fixative [28] . Sections were incubated overnight with primary antibodies (Suppl . Table 5a ) and processed using a commercial immunostaining kit (PerkinElmer Life Science, Boston, MA) based on tyramide signal amplification [1] . Numerous immunostained sections were sequentially double-stained with additional antibodies (Suppl. animals (N = 3-5), immunostained for TH, were captured on a Vslide scanning microscope (Metasystems). The number of 'single swollen varicosities/intervaricose connections' and 'aberrant fiber clusters'/mm 2 was determined in unilateral fronto-parietal cortices as described before [3] . A detailed description of these aberrant structures is reported in the "Results" and Fig. 7 , Suppl. Figure 2, legends) . To determine the TH + fiber density, we applied a one-pixel algorithm using the Image J 1.37v in micrographs.
Semiquantitative score of aberrant noradrenergic structures
A four-grade score was applied at numerous rostro-caudal levels ( Table 1, Quantitative in situ hybridization (qISH) Mice (4 months old, N = 5/genotype) were decapitated and the brains rapidly dissected and snap-frozen. Antisense oligoprobes (TH, galanin), complementary or highly homologous to the mouse mRNA sequence, were synthesized by CyberGene AB (Huddinge, Sweden). The oligonucleotides were radioactively labeled with 33 P, and sections were hybridized as described [92] and dipped in Kodak NTB-2 emulsion (Kodak, Rochester, NY). The transcript levels for TH and galanin expression in LC were quantified using an image analysis system (see SI). The number of silver grains was measured over the cell bodies with the Image J 1.37v software.
HPLC measurement of monoamines
Mice (2 weeks and 4 months old, N = 5/genotype) were decapitated and fronto-parietal cortex, caudate-putamen and dorsal hippocampus samples were dissected and homogenized. Concentrations of NA, dopamine (DA), serotonin (5-hydroxytryptamine, 5-HT) were determined by HPLC as described [57] . The chromatograms were recorded and integrated by the use of computerized data acquisition system Clarity (DataApex, Prag, Czeck Republic).
Statistical analyses
One-way ANOVA and Fisher post hoc tests were applied for human qPCR studies. Student's t test for independent samples was applied for the evaluation of densitometry on human TMA slides. One-and two-way ANOVA (quantification of aberrant fiber structures, fiber density measurements, respectively) and Tukey's post hoc test; three-way ANOVA and Tukey test (HPLC measurements) and Student's t test for independent samples (qISH, cell body or somatic surface area, HPLC) were applied for animal studies. All data were evaluated with acceptable levels of significance set at P < 0.05 using Statistica ® 7 software. All variables, numerical data of ANOVA F/df and main effect P values are reported in Suppl. Tables 6, 7 . 
Results

Somatodendritic localization of SSTR2a in the human LC
To determine the precise localization of SSTR2 in the LC region, perfused non-neurodegenerative human brainstems were studied. Prominent somatodendritic SSTR2a localization was found in many LC noradrenergic (TH-immunoreactive, IR) neurons in both examined human brainstems but not in other nuclei at the level of LC (Fig. 1a-d ).
Decreased SSTR2 expression in the LC of Alzheimer's subjects
To determine the expression level of SSTR2, micro-punch samples from the LC were collected from verified Braak III-IV and V-VI stage subjects and age-matched controls (Suppl. Table 2 ). SSTR2 mRNA expression levels were high in controls, compared to those of galanin (GAL) or galanin receptor 3 (GALR3), members of another inhibitory neuropeptide system expressed in LC neurons ( Fig. 2a ; a higher Ct value reflects a lower expression level). SSTR2 expression significantly decreased in both Braak III-IV (−48 %) and Braak V-VI (−45 %) groups compared to the age-matched controls. The transcripts for neuron-specific microtubule-associated protein (MAP2) also decreased significantly in the Braak III-IV group (−68 %) but, interestingly, its expression level was again increased in the Braak V-VI group (Fig. 2b) . SSTR2 and MAP2 expressions did not correlate with age, gender or postmortem delay (PMD) (data not shown).
No significant changes in transcript levels for TH, the rate-limiting enzyme of noradrenaline synthesis, dopamine β-hydroxylase (DBH), GAL or GALR3 were noted in either Alzheimer's groups, compared to age-matched controls. However, a trend towards increase both in TH and GALR3 (Fig. 2b ) expression was found in the Braak III-IV group.
Relative fold changes for SSTR2 gene expression levels were normalized to β-III-tubulin (TUBB3) as well as to β-ACTIN and GAPDH with similar results (Fig. 2c , Suppl. Table 7 ).
Decreased SST immunostaining and aberrant TH-IR fibers in the temporal cortex of Alzheimer's subjects Next, we examined the SST immunostaining and the morphology of TH-IR fibers in the human brain, with the application of the tissue micro-array (TMA) technique (Fig. 3a) . In the Alzheimer subjects (Braak V-VI, N = 7), dystrophic neurites and neurofibrillary tangles were immunostained for tau-PHF throughout the TMA temporal cortex samples, and senile plaques were stained for amyloid-β (Fig. 4d, g ). In contrast, no amyloid-β or tau-PHF staining was noted in the controls (with a single exception for amyloid-β) (Fig. 4) .
In control samples, a dense network of SST-IR processes was strongly immunostained (Fig. 4a, b) , which was significantly decreased in the Alzheimer's samples (Fig. 4c, d,  g ), in agreement with previous reports [76] .
In both control and Alzheimer's samples, rare varicose TH-IR fibers with normal morphology were immunostained (Fig. 3b, c) . In samples from 3 of 10 Alzheimer's subjects, occasional clusters of aberrant TH-IR fiber structures were noted (Fig. 3d-g ). These clusters were 50-100 μm in diameter, contained loose conglomerates of enlarged-swollen varicosities (Fig. 3e, g ), were negative for tau-PHF (Fig. 3d, f) and were unrelated to the location of amyloid plaques (Fig. 3d, f) .
Noradrenergic but not dopaminergic, serotonergic or cholinergic neurons express SSTR2a in mouse
Further experiments were carried out on different Sstr knockout mouse strains and their wild-type littermates (Suppl. Figure 1) . First, we examined the SSTR2 protein expression of various monoaminergic and cholinergic neuron populations. A strong somatodendritic SSTR2a staining was seen in the LC and all other examined NA cell groups in Sstr2 +/+ (WT) animals (A1, A2, A6-LC, A6r and A7; see [26] ) (Fig. 5a-b) , in agreement with a strong β-galactosidase immunostaining (sstr2 lacZ staining) in the LC neurons of Sstr2 −/− (knockout) mice (Fig. 5c , upper panel). Importantly, sstr1 lacZ or sstr4 lacZ staining was never found in the LC NA neurons (Fig. 5c , medial, lower panels, respectively). Moreover, serotonergic, dopaminergic and cholinergic neurons did not show co-localization with SSTR2a (Fig. 5d ).
Selective noradrenergic axonal degeneration in Sstr2
−/− animals In Alzheimer's disease, the noradrenergic system shows a marked vulnerability. SSTR2/Sstr2 is highly expressed in the noradrenergic LC neurons both in human and mouse, and we found an early decrease in SSTR2 expression in LC of Alzheimer's subjects. We, therefore, examined the morphology of the noradrenergic projections of Sstr2 −/− mice. The density of fibers positive for NET, DBH and, in many regions also for TH, was reduced in 4-month-old Sstr2 −/− but not in Sstr1 −/− or Sstr4 −/− animals (Fig. 6a,  c, d ). In addition, swollen NET + , DBH + or TH + fibers and sometimes large aberrant fiber clusters could be detected, exclusively in Sstr2 −/− animals (Figs. 6a-d, 7, Suppl. Figure 2 and legends) . The fiber clusters intermingled with hypertrophic microglial or astroglial cells (Fig. 6b) ; they co-localized galanin (Fig. 6c ) but were not immunoreactive SSTR2 is expressed at almost as high level as for TH, compared to GAL and GALR3, the most abundant galanin receptor in LC [62] . Note that the Ct values are inversely proportional the amount of detected RNA. b The expression level of SSTR2 is significantly decreased in Alzheimer's disease Braak III-IV and V-VI stages. MAP2 expression is decreased only in the Braak III-IV stage. Relative expression levels (fold changes) were calculated by normalizing Ct values to TUBB3 as reference gene and subsequently to the average of controls. Fold changes were calculated by the comparative CT method (2
−ΔΔCT
). Values for controls were set to 1.00. c Relative expression level of SSTR2, where Ct values were normalized to TUBB3, ACTIN or GAPDH as reference genes. Statistical analysis: one-way ANOVA and Fisher Test for post hoc test for comparisons (N = 8, N = 5, N = 7, control, AD Braak III-IV, AD Braak V-VI, respectively; Asterisk significant difference between control and AD cases, hash significant difference between AD Braak III-IV and AD Braak V-VI cases). Data are expressed as mean ± SEM Fig. 3 Aberrant TH-immunoreactive fibers in the temporal cortex of Alzheimer's disease brains. a Tissue micro-array (TMA) slide with 1-mm-diameter temporal cortical punch samples of Alzheimer's disease subjects (in squared boxes) and control subjects. (The TMA slide also contained DLB cases, which were not analyzed in the present study). The slides were triple stained for TH, amyloid-β and Tau-PHF and were counterstained with the nuclear staining DAPI. for β-amyloid (Suppl. Figure 3) . However, morphology and density of fiber networks positive for tryptophan hydroxylase-2 (TPH2), the dopamine transporter (DAT) or choline acetyltransferase (ChAT) appeared normal (Fig. 6d) .
Decreased NA levels in the Sstr2
−/− animals To validate our morphological data, we then measured levels of monoamines and their main metabolites in Sstr2
and WT mice. Indeed, NA levels were significantly decreased in the fronto-parietal cortex and hippocampus but not in the striatum at 4 months of age. In contrast, there was no decrease in DA or serotonin levels in any region. At 2 weeks of age, NA levels were decreased in the hippocampus but not in fronto-parietal cortex or striatum. Serotonin levels were not altered at 2 weeks of age, but striatal DA levels were slightly increased (Fig. 6e) .
Morphological, temporal and spatial characterization of noradrenergic axonal degeneration in Sstr2 −/− mice Next, we morphologically and quantitatively/semiquantitatively analyzed the noradrenergic degeneration in our knockout model. Fiber aberrations were divided into two categories: single swollen varicosities/intervaricose connections and dense clustering of aberrant/degenerating fibers (fiber clusters) ( Fig. 7 and Suppl. Figure 2) . The single swollen varicosities/intervaricose connections were usually 5-7 μm in diameter and exhibited dense staining compared with neighboring normal noradrenergic fibers ( Already 1 month postnatally, the TH-IR fiber density in the fronto-parietal cortex was significantly decreased compared to the age-matched wild-type mice, and decreased further with age (Figs. 7a, d-f) . However, single, swollen varicosities were apparent already at 2 weeks of age, reaching a maximum at 4 months of age and then gradually disappearing (Fig. 7b) . In parallel, aberrant fiber clusters steadily increased until 8 months of age (Fig. 7c) .
Signs of degeneration appeared globally in the Sstr2
brains, extending from the olfactory bulb to the brainstem, being most severe in neocortex, thalamus, amygdala and hippocampus. Hypothalamus, the septal region and certain brainstem areas were clearly less affected ( Table 1 ). The decrease of NA terminals was also seen in the lumbar spinal cord, especially in the dorsal horn, but no aberrant fiber clusters could be detected here (Fig. 8a, b ).
Noradrenergic LC cell bodies do not degenerate in Sstr −/− mice Next, we examined the integrity of LC perikarya to investigate whether or not the noradrenergic degeneration also affected the cell bodies. The number of TH-IR cell bodies and their average soma size were not altered in 8-monthold Sstr2 −/− mice compared to wild-type littermates (Fig. 9a-d) . However, TH mRNA levels in the LC were modestly decreased already at 4 months of age (Fig. 9e-g ). The expression of the modulatory neuropeptide galanin did not change significantly (Fig. 9h) .
Peripheral noradrenergic nerves do not show signs of degeneration
To investigate whether degeneration also affects the peripheral nervous system, we examined some peripheral organs well known for a high density of noradrenergic innervation. However, NET immunostaining of salivary gland and jejunum samples did not show any sign of NA denervation or axonal degeneration (Fig. 10d-f ). In agreement, only very few neurons exhibited a weak/moderate SSTR2a immunostaining in the superior cervical ganglion, the main source of the noradrenergic innervation of peripheral organs in the head region (Fig. 10a-c) .
Discussion
In Alzheimer's and other neurodegenerative disorders, there is a serious noradrenergic impairment, including an early and marked degeneration of LC neurons. In the present study, we show expression of SST receptor subtype-2 protein in noradrenergic LC neurons of control human brains, as well as a decrease in levels of its transcript already in the early stage of Alzheimer's disease. Also, the deletion of this single receptor in a mouse model causes an earlyonset, global, selective and progressive noradrenergic axonal degeneration, most distinctly associated with projections from the LC. Serotonergic, dopaminergic and cholinergic fibers, however, do not degenerate. This selectivity of impairment for the noradrenergic system is confirmed by biochemical analyses. Remarkably, all NA cell groups examined, but no 5-HT, DA or cholinergic neurons, express the SST subtype-2 receptor. Additional discussion notes are provided in the SI (indicated as "SI-D1-3" in the following).
Decreased SSTR2 expression in LC in Alzheimer's disease
The density of SST binding sites in the LC is very high, both in the human and rodent brain [21] . In agreement, we here show a high mRNA expression level of SSTR2 and a strong somatodendritic immunostaining for SSTR2 protein in the human LC. SSTR2 expression was, however, significantly decreased already in the early stages of neurodegeneration (with intermediate Alzheimer's disease neuropathological changes, Braak stage III/IV), when cognitive impairment but no dementia of patients occurs [75] . The LC noradrenergic neurons themselves do not express SST, i.e., the peptide [67] . According to early experimental studies, the SST innervation of LC mainly originates in the hypothalamus [80] , where the SST levels are also decreased in Alzheimer's subjects, as they are in many cortical regions [76, 108] . These findings suggest impairment also of the LC-SST system in Alzheimer's disease. In contrast, another inhibitory neuropeptide receptor expressed in the human LC, the GALR3 [62] , showed even a trend to increase in mRNA concentration in the Braak III-IV stage. The expression of MAP2, a dendrite-and soma-specific microtubule-associated protein [83] is decreased in Braak III-IV samples, as expected. However and interestingly, no change in MAP2 expression was noted in the Braak V-VI stage, compared to control, which supports a previous report on dendritic spouting of remaining LC neurons in the terminal phase of Alzheimer's disease [99] . mRNA expression of TH, the rate limiting enzyme of NA synthesis, and of DBH did not decrease, in agreement with previous studies [70, 99] .
Interestingly, LC cell death is either very limited or nonexistent in transgenic mice models of Alzheimer's disease [115] . Thus, in the next part of our study we applied knockout mice for different SST receptors (SSTR1, 2, 4) and their wild-type littermates, to further study a potential role of SSTR2 signalling in the maintenance of the noradrenergic system. We show that Sstr2 is expressed at high levels in all examined noradrenergic nuclei, including LC, and in neocortical areas, while Sstr1 and Sstr4 are expressed in the mouse cortex but not in the LC.
Selective noradrenergic axonal degeneration in Sstr2
−/− brains The noradrenergic degeneration in Sstr2 −/− mice was investigated using immunostaining for three noradrenergic markers (TH, NET, DBH), and galanin [100] , the latter a neuropeptide expressed in LC neurons [71] . In contrast, no degenerative features in serotonergic, dopaminergic or cholinergic fibers were found, further underlining the selectivity of this degenerative process for the noradrenergic system, also supported by the HPLC regional measurements of NA, 5-HT and DA.
All three noradrenergic markers showed enlarged/swollen varicosities/intervaricose connections and clusters of aberrant fibers, in parallel with a substantial decrease of fiber densities. Such features have already been reported for serotonergic and cholinergic systems in normal, aging rats [3, 7, 77, 110] , as well as in the entire monoaminergic system of Zitter mutant or microencephalic rats [106, 114] . Enlarged/swollen varicosities are generated by accumulations of intra-axonal materials as a result of impaired axonal transport due to destabilization of microtubules. The knot-like fiber clusters are formed following the gradual degeneration of intervaricose connections [4, 109, 110] .
The noradrenergic, axonal degeneration in Sstr2 −/− animals is global, starts early and gradually progresses with the first distinct appearance of enlarged varicosities at around 2 weeks of age, followed by a gradual cluster formation from 2 months of age (ESM SI-D1). The decrease of NA levels in general parallels the loss of noradrenergic terminals (ESM SI-D2). However, the LC cell bodies seem morphologically preserved with only a modest decrease of TH mRNA levels, in any case up till 8 months of age, suggesting that the degeneration in Sstr2 −/− animals primarily affects the axons. However, there was no evidence for degenerative processes in the peripheral noradrenergic sympathetic nerves/axons [78] , or in dopaminergic, serotonergic or cholinergic neurons, which all lacked SSTR2 immunostaining, except for a few cells in the superior cervical ganglion. Finally, there was no degeneration detected in the noradrenergic projections of Sstr1 −/− and Sstr4 −/− mice. In agreement, sstr1
LacZ or sstr4 LacZ staining, respectively, was never found in the brainstem NA cells of these knockouts.
Possible mechanisms underlying the noradrenergic axonal degeneration in Sstr2
−/− mice
Disturbed development/trophism
There is evidence that SST has trophic effects on neurite outgrowth [37, 38] . Our previous results on dorsal root ganglia indicate that a SST-SSTR2a complex can be retrogradely transported [95] , perhaps mediating intracellular, trophic effects in a similar way as nerve growth factor (NGF) [63] . Thus, one explanation might be that absence of SSTR2 prevents retrograde transport of SST required for proper maintenance and development of intact NA axons and nerve terminals. 
Attenuated somatodendritic inhibition and dysfunctional stress axis
SST receptors dampen the stress system [96] , of which the LC is an important node (see Introduction). ACTH levels were previously found to be increased in Sstr2 knockouts [113] . The LC neurons express Sstr2 at high levels from the embryonic age till adulthood [101] , and the postsynaptic SSTR2 mediates a strong inhibitory action of SST on spontaneous firing of LC neurons [23] . Our results confirm that LC neurons and all examined NA cell groups express a strong somatodendritic but no detectable axonal SSTR2 immunostaining postnatally in mouse; and these are the neuron groups associated with axonal degeneration. We hypothesize that the chronic absence of somatodendritic SSTR2-mediated inhibition of NA neurons leads to a continuous overexcitation and a slow, selective degeneration/ accelerated aging of noradrenergic axons due to oxidative stress.
Aberrant TH-IR fibers in the temporal cortex of Alzheimer´s subjects Despite the well-established neuronal cell body loss in LC, we do not know of any comprehensive studies on the morphology of noradrenergic axonal arborization in Alzheimer's disease. Nevertheless, NA levels [2, 81] and DBH activity [25] are decreased in Alzheimer's frontal-temporal cortical samples, supporting loss of NA fibers.
Using TMA slides, we show clusters of apparently aberrant TH-IR fibers with enlarged varicosities from some terminal-phase Alzheimer's subjects, which are similar in morphology and size to the degenerating noradrenergic fiber clusters found in Sstr2 −/− mice. However, in addition to noradrenergic fibers, TH also labels a substantial number of dopaminergic fibers in the human neocortex [43] . More advanced techniques are required for the detailed morphological and quantitative spatial analysis of noradrenergic axonal arborization in human postmortem brain samples from neurodegenerative diseases.
The behavioral phenotype of Sstr2 −/− mice Sstr2 knockout/LacZ knockin mice show impaired motor coordination [6] , and another Sstr2 knockout strain exhibits locomotor and exploratory deficits, as well as enhanced anxiety-like behavior (ESM-SI-D3). Moreover, enhanced glutamate transmission in the hippocampus of young Sstr2 knockouts was described [31, 113] , perhaps due to reduced SST-mediated inhibition of glutamate release [33] . This Sstr2 −/− behavioral phenotype is comparable with a dysfunctional noradrenergic system. Thus, DBH −/− mice show deficits in social discrimination, reduced exploratory activity in novel environments, decreased locomotor activity in novel stimulation and impaired motor coordination [66, 86] . Moreover, rats with axonal NA degeneration after treatment with the neurotoxin DSP4 exhibit neophobic behavior [50] , very much resembling the Sstr2 −/− behavioral phenotype.
Implications for neurological and mental disorders SST was found to be the most consistently reduced neuropeptide in Alzheimer's disease [19, 20, 27, 58, 89] . The SST deficit correlates well with the dementia score in Alzheimer's disease but less so with progression of neuropathology [30] , indicating association mainly with cognitive impairment [34, 112] .
Pre-clinical and clinical trials have indicated that a SST release enhancer (FK962) or the SST analog octreotide (sandostatin) improves memory [24, 102] , but finally none of them passed the phase 3 trial. Recent pre-clinical studies, however, reported that FK962 combined with the AChE inhibitor donepezil (Aricept) has a significantly greater effect on cognition than either compound alone [69] . This supports the notion on the necessity of combined therapy of Alzheimer's disease, a multisystem disorder affecting multiple neuronal populations [29] .
Several clinical and experimental studies indicate that the SST system is also implicated in stress, anxiety and depression [64] , and there is now direct evidence that, in fact, the receptor involved is SSTR2 [32, 33, 118] . Notably, depression is a leading neuropsychiatric complication in Alzheimer's disease [94] , and an association with chronic life stress and later-life cognitive dysfunction has been proposed [46] .
Concluding remarks
The main goal of our studies was to elucidate potential factors underlying the well-documented vulnerability of the noradrenergic LC neurons in Alzheimer's disease. It has been proposed that the evolutionary fast and large increase in brain volume, including the expansion of the long and poorly myelinated diffuse cortical projections of subcortical nuclei, such as LC, have made these evolutionary old, subcortical structures more vulnerable to agerelated challenges specifically in the human brain [14, 15] . Consequently, the currently used Alzheimer mouse models do not appear suitable for the study of pathomechanisms responsible for neurodegeneration of the LC in Alzheimer's disease. Therefore, we turned to another experimental approach based on the facts that (i) SST is significantly decreased in the cortex and hypothalamus in Alzheimer's disease, and (ii) one of its receptors, the SSTR2, is highly expressed not only in rodent but also, as shown here, in the human LC. −/− animals. The noradrenergic fiber density gradually decreases, while the number of aberrant fiber structures (swollen, enlarged varicosities, arrowheads in e*; fiber clusters, arrowheads in f, f*) gradually increases with age. d, e, f Low-power overviews of somatosensory-parietal-retrosplenial cortices; d*, e*, f* higher magnification micrographs from somatosensory cortex. g-j Confocal analysis of aberrant noradrenergic structures (merged micrographs of 0.5-μm-thick optical layers along the Z-stack). The single swollen varicosities/intervaricose connections (5-7 μm in diameter; h arrows) are easily identifiable due to their morphology and dense staining compared with neighboring normal noradrenergic fibers (g). The knot-like fiber clusters ['loose type' (i); 'compact' (j)] comprise aggregated, irregular-shaped, tortuous fibers with a high number of concentrated swollen varicosities/intervaricose connections. These clusters are distinct and appear as an interruption of the adjacent normal fiber pattern. Their size varied approximately from 50 to 250 μm. The single swollen varicosities/intervaricose connections and the distinct fiber clusters are visualized in the same manner using antibodies to NET, TH or DBH. These aberrant structures are virtually not detected in the WTs. Scale bars 500 µm in d, applies to d, e and f; 100 µm in f*, applies to d*, e* and f*; 25 μm in g, applied to g and h; 100 μm in i, applies to i and j
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The present findings of an early, selective and global axonal degeneration of noradrenergic projections in Sstr2 −/− mice suggest that SSTR2 is critically involved in the maintenance and integrity of the noradrenergic system, a widespread brain network of fundamental importance for the regulation of arousal, stress and emotions, memory functions and motor coordination. Based on these animal data, we propose that an early decrease of SSTR2 expression in the LC of Alzheimer's disease subjects, in agreement with the present results on Alzheimer brains, may be an important component of the vulnerability of LC projections. Our data support a scenario, in which reduced SST neurotransmission and SSTR2 receptor-mediated signaling in noradrenergic LC neurons contributes to the loss of noradrenergic innervation of the forebrain in Alzheimer's disease. Noradrenergic impairment results in mood and other behavioral changes and accelerates AD pathology as shown by others [48, 52, 85, 98] . Finally, our results point to the SSTR2 as potential drug target for neurodegenerative and/or neuropsychiatric disorders, perhaps as part of a combined pharmacotherapy. 
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